Figure 8

Supervised Clustering of the results of Bovela treatment (group C), three components with only the most promising features. (A) PLS-DA using blood parameters (AUROC: “pre” vs others: 0.875, “post” vs others: 0.791, “late” vs others: 0.996); (B) PLS-DA using milk parameters (AUROC: “pre” vs others: 0.872, “post” vs others: 0.869, “late” vs others: 0.955).